TNF Inhibitor denied as non-formulary by Aetna?

Aetna's specific coverage criteria for tnf inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Your TNF Inhibitor as Non-Formulary — and What You Can Do

Tumor Necrosis Factor (TNF) inhibitors are an established class of biologics with multiple FDA-approved agents. Aetna maintains a tiered formulary and may exclude specific TNF inhibitors — or place them at a non-covered tier — in favor of a preferred agent within the same class. A non-formulary denial means the specific product your prescriber requested is not on Aetna's active drug list for your plan, even if other TNF inhibitors are covered.

This denial is appealable through a formulary exception process. Formulary decisions are plan-level administrative choices; exception requests are the mechanism for overriding them when a specific agent is medically necessary for your individual case and the preferred alternative is clinically inappropriate.

## Federal Appeal Rights

• Formulary exception request: Most plans are required under ACA and state law to have a formulary exception process. Your prescriber submits a request demonstrating that the preferred formulary alternative is contraindicated, has previously failed, or is otherwise not clinically appropriate for you.
• Internal appeal: If the formulary exception is denied, you may appeal the adverse determination. File within the deadline on your denial notice. You are entitled to request the formulary tier criteria and the clinical basis for the preferred-agent designation.
• External review (ACA §2719 / ERISA §503): After internal exhaustion, escalate to an independent review organization within approximately four months of the final adverse determination. Formulary exception denials are reviewable for clinical appropriateness.
• Expedited review: Available if delay in accessing the non-formulary agent would seriously harm your health.

## What to Gather

• Prescriber's formulary exception letter: The core document. Your specialist must explain why the formulary-preferred TNF inhibitor is not appropriate for your case — prior failure, documented intolerance, contraindication, or a clinical distinction that makes the non-formulary agent specifically indicated.
• Trial history with preferred alternatives: If you have already tried and failed the preferred formulary agent, provide dated chart notes, lab results, and the documented clinical reason for switching.
• Diagnosis and disease-activity documentation: Current chart notes showing your diagnosis, severity, and ongoing need for TNF inhibitor therapy.
• FDA labeling comparison: If the non-formulary agent has an approval or labeled indication that the preferred alternative lacks for your specific condition, note that distinction.
• Applicable guideline support: Reference to the relevant specialty society guideline organization (e.g., ACR, AGA, AAD) that supports the use of the specific agent for your indication.

## Criteria-Mapping Structure

Obtain Aetna's formulary exception policy and the Clinical Policy Bulletin for the TNF inhibitor class. Identify why the non-formulary agent was requested and what the preferred alternative is. Your appeal should directly address each exception criterion: (1) prior failure of the preferred agent with chart evidence, or (2) clinical contraindication with supporting documentation, or (3) unique indication supported by the FDA label or recognized guidelines.